A falsely low free light chains, type lambda (flc lambda) result was obtained on a patient sample that was diluted 1:5 on a bn ii system using n latex flc lambda reagent.The sample was rerun using a 1:20 sample dilution for flc lambda on the same system, recovering higher.The sample was then rerun using a 1:100 sample dilution for flc lambda on the same system, recovering higher.The sample was then sent to an alternate laboratory and was run for flc lambda using a non-siemens assay, recovering higher.The higher result obtained using the non-siemens assay was reported, as the correct result, to the physician(s).There are no known reports of patient intervention or adverse health consequences due to the falsely low flc lambda results.
|
Siemens filed the initial mdr 9610806-2023-00008 on 10-mar-2023.Additional information (14-mar-2023): the affected sample was provided for analysis.During internal testing, the sample was rerun for flc lambda with a higher sample dilution, and the flc lambda result recovered higher.It was determined that the sample contained a high level of immunoglobulin a (iga) lambda, which interfered with free light chains, type lambda (flc lambda) measurements at low sample dilutions.As per the n latex flc lambda instructions for use (ifu): "excessively elevated monoclonal immunoglobulin concentrations might have the potential to suppress the reaction of anti-flc antibodies with free light chain molecules.In addition, other conditions may cause lower flc concentrations, e.G., bi-clonal after therapy, polymerization of lambda chains, etc.If results do not fit to previous ones, or to results of other tests (e.G., serum and urine protein electrophoresis, immunofixation, differential blood cell count) and/or to the clinical situation, it is recommended to re-analyze the sample in a higher sample dilution." the assay performance is in accordance with the ifu.The reagent is performing according to specifications.No further evaluation of this device is required.
|